source
- Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollmentDr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…
- Zanubrutinib shows longer overall survival than ibrutinib in real-world relapsed/refractory mantle cell lymphomaA retrospective real‑world analysis examined outcomes of covalent BTK inhibitors in patients with relapsed or refractory mantle cell lymphoma who received treatment in the second or third line. Th…